Cardiff Oncology, Inc. Common Stock CRDF
$0.96
-2.13%
at last close
Recent SEC Filings
| Form | Description | Filed | Document |
|---|---|---|---|
| 8-K | 8-K | 2026-08-11 | View → |
| 10-Q | 10-Q | 2026-08-11 | View → |
| 4 | 4 | 2026-07-16 | View → |
| 4 | 4 | 2026-07-16 | View → |
| 8-K | 8-K | 2026-07-16 | View → |
| 424B5 | 424B5 | 2026-07-16 | View → |
| 4 | 4 | 2026-06-22 | View → |
| 4 | 4 | 2026-06-22 | View → |
| 4 | 4 | 2026-06-15 | View → |
| 4 | 4 | 2026-06-15 | View → |
| 4 | 4 | 2026-06-15 | View → |
| 4 | 4 | 2026-06-15 | View → |
| 4 | 4 | 2026-06-15 | View → |
| 8-K | 8-K | 2026-06-11 | View → |
| 8-K | 8-K | 2026-06-03 | View → |
| 8-K | 8-K | 2026-05-29 | View → |
| 8-K | 8-K | 2026-05-19 | View → |
| 8-K | 8-K | 2026-05-14 | View → |
| 10-Q | 10-Q | 2026-05-14 | View → |
| 4 | 4 | 2026-04-28 | View → |
| DEF 14A | DEF 14A | 2026-04-23 | View → |
| 4 | 4 | 2026-04-16 | View → |
| 4 | 4 | 2026-04-16 | View → |
| 8-K | 8-K | 2026-04-09 | View → |
| 4 | 4 | 2026-04-02 | View → |
| 8-K | 8-K | 2026-04-02 | View → |
| 8-K | 8-K | 2026-02-25 | View → |
| 8-K | 8-K | 2026-02-24 | View → |
| 10-K | 10-K | 2026-02-24 | View → |
| 4 | 4 | 2026-02-18 | View → |
| 4 | 4 | 2026-02-18 | View → |
| 8-K | 8-K | 2026-01-27 | View → |
| 8-K | 8-K | 2025-11-06 | View → |
| 10-Q | 10-Q | 2025-11-06 | View → |
| 4 | 4 | 2025-07-31 | View → |
| 8-K | 8-K | 2025-07-29 | View → |
| 10-Q | 10-Q | 2025-07-29 | View → |
| 4 | Insider transaction | 2025-06-30 | View → |
| 4 | Insider transaction | 2025-06-30 | View → |
| 4 | Insider transaction | 2025-06-30 | View → |
Filings are sourced directly from the SEC's EDGAR system. Annual reports (10-K) and quarterly reports (10-Q) carry the full financial statements; 8-K filings disclose material events between reports; Form 4 filings record insider purchases and sales.
Key Stats
- Last Close
- $0.96
- Market Cap
- $77.06 million
- 52-Week Range
- $0.76 – $4.55
- Average Volume
- 1.42 million shs
Data is delayed and provided for informational purposes only. Not investment advice. See our disclaimer.
